Skip to Content

'
Faye M. Johnson, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: Unit 432
Houston, TX 77030
Room Number: FC9.3036
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

Degree-Granting Education

1996 University of Texas Medical School at Houston, Houston, TX, MD, Medicine
1996 University of Texas Graduate School of Biomedical Sciences MD Anderson Cancer Center, Houston, TX, PHD, Cancer Biology
1989 The Johns Hopkins University, Baltimore, MD, BA, Biology

Postgraduate Training

6/2002-6/2003 Chief Medical Oncology Fellow, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
2000-2002 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1997-2000 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX

Board Certifications

2003 Medical Oncology
2000 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-8/2010

Administrative Appointments/Responsibilities

Chief, Section of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2012-present

Institutional Committee Activities

Vice Chair, Medical Practice Committee, MD Anderson Cancer Center, 2011-2013
Member, Faculty Senate Committee, MD Anderson Cancer Center, 9/2010-8/2012
Chair, Faculty Appeals Committee, MD Anderson Cancer Center, 7/2009-present

Honors and Awards

2013 LCRF Scientific Merit Award, Lung Cancer Research Foundation
2011 Nominee in Recognition of Mentoring Excellence, MD Anderson Post-Doctoral Association
2010 Nominee in Recognition of Mentoring Excellence, MD Anderson Post-Doctoral Association

Selected Publications

Peer-Reviewed Original Research Articles

1. Gonzalo Recondo, Busaidy Naifa, Erasmus Jeremy, Wiliams Michelle D, Johnson Faye M. Spindle Epithelial Tumor with Thymus-like Differentiation (SETTLE): A Case Report, Comprehensive Review of the Literature, and Treatment Recommendations. Head and Neck. In Press.
2. Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY. Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β3-Src Pathway. J Natl Cancer Inst. 10/2013.
3. Guo C, Shao R, Correa Am,Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Rotha JA, WistubaII, Swisher SG, Lin T, Pataer, A. Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC. Journal of Thoracic Oncology 8(3):301-8, 3/2013. PMID: 23370317.
4. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 80(3). e-Pub 2/2013. PMID: 23485129.
5. Saintigny P, Peng S, Zhang B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 11. e-Pub 7/2012. PMID: 22807579.
6. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib. Sci Transl Med 4(136):136ra70, 5/2012. PMID: 22649091.
7. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18(1):127-39, 1/2012. e-Pub 11/2011. PMCID: PMC3251692.
8. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 5/2011. e-Pub 11/2010. PMCID: PMC3117018.
9. Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and C-Met in mediating resistance to c-Src inhibition in head and neck Cancer. Clin Cancer Res 17(3):514-24, 2/2011. e-Pub 11/2010. PMID: 21106725.
10. Sen B, Johnson FM. c-Src Family of Tyrosine Kinases. Encycolopedia of Signaling Molecules Part 4:473-480, 2011.
11. Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011:865819, 2011. e-Pub 4/2011. PMCID: PMC3135246.
12. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol 28(30):4609-4615, 10/2010. e-Pub 9/2010. PMCID: PMC2974341.
13. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 3(7):800-9, 7/2010. e-Pub 6/2010. PMCID: PMC2900459.
14. Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in Lung Cancer: Current Status and Future Directions. Clin Lung Cancer 11(4):238-42, 7/2010. PMID: 20630825.
15. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist Updat 13(3):67-78, 6/2010. e-Pub 5/14/2010. PMID: 20471303.
16. Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. J Thorac Oncol 5(6):S207, 6/2010. PMID: 20502275.
17. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-27, 5/2010. e-Pub 2/2010. PMCID: PMC3378055.
18. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small celllung carcinoma. Cancer 116(10):2409-15, 5/2010. PMID: 20225329.
19. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Phase I, Pharmacokinetic, and Drug Interaction Study of Dasatinib in Patients with Advanced Solid Tumors. Cancer 116(6):1582-91, 3/2010. PMID: 20108303.
20. Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2(12):1039-49, 12/2009. e-Pub 11/2009. PMID: 19934338.
21. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 11/15/2009. e-Pub 10/27/2009. PMCID: PMC2935176.
22. Johnson FM, Glisson BS. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol 6(10):562-3, 11/2009. PMID: 19786998.
23. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer. Clin Cancer Res 15(13):4423-30, 7/2009. e-Pub 6/2009. PMID: 19531623.
24. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 69(5):1958-65, 3/2009. e-Pub 2/2009. PMCID: PMC2929826.
25. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 26(20):3460-2, 7/2008. PMID: 18612164.
26. Saigal B, Glisson BS, Johnson FM. Dose-and Sequence-dependent Cyotoxicity of Erlotinib and Docetaxel in Head and Neck Squamous Cell Carcinoma. Anticancer Drugs 19(5):465-475, 6/2008. PMID: 18418213.
27. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: associationof Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112(9):2088-100, 5/2008. PMID: 18327819.
28. Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952-60, 4/2008. PMCID: PMC3378059.
29. Johnson FM and Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651-9, 11/2007. PMID: 18045060.
30. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src Kinase Inhibition results in Synergistic Antitumor Effects. Clin Cancer Res 13(14):4233-4244, 7/2007. PMID: 17634553.
31. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 7/2007. PMID: 17620427.
32. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-76, 1/2007. PMCID: PMC1762707.
33. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in small cell lung cancer cells. Cancer 106(2):366-74, 1/2006. PMID: 16342249.
34. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 11/2005. PMID: 16199307.
35. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19):6924-32, 11/2005. PMID: 16203784.
36. Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cell. J Cell Physiol 205(2):218-27, 11/2005. PMID: 15887238.
37. Johnson FM, Yang P, Newman RA, Donato NJ. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. J Exp Ther Oncol 4(4):317-25, 12/2004. PMID: 15844661.
38. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of Docetaxel and Carboplatin as Neoadjuvant Therapy for patients with advanced Nasopharyngeal Carcinoma. Cancer 100(5):991-8, 3/2004. PMID: 14983495.
39. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 7/2003. PMID: 12886869.
40. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I Study of Dose-Dense Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer. Clin Lung Cancer 5(1):40-5, 7/2003. PMID: 14596703.
41. Kim ES, Johnson F, Hong WK, Khuri FR. Strategies in the Chemoprevention of Lung Cancer. Chemoprevention, 2003.
42. Johnson FM, Shur BD. The level of cell surface beta1,4-galactosyltransferase I influences the invasive potential of murine melanoma cells. J Cell Sci 12(16):2785-95, 7/1999. PMID: 10413685.
43. Johnson FM, Garcia A. Sepsis with group B streptococci (Streptococcus agalactiae) secondary to urinary tract infection in an adult male. J Am Geriatr Soc 47(5):629-30, 5/1999. PMID: 10323662.

Abstracts

1. Faye M. Johnson, XiMing Tang, Hai T. Tran, Chelsey Mc Intyre, Justina Price, J. Jack Lee, Nusrat Harun, Ignacio Ivan Wistuba, Kathryn A. Gold. A phase I/II study combining dasatinib (D) and erlotinib (E) in non-small cell lung cancer. American Society of Clinical Oncology, Annual Meeting, Chicago, Illinois, 2013.
2. Peng S, Sen B, Mazumdar, Myers J, Bell D, Williams M, EL-Naggar A, Johnson FM. Establishing a patient-derived heterotransplant mouse model of head and neck squamous carcinoma (HNSCC). American Association for Cancer Research Annual Meeting, Chicago, Illinois (#2361), 3/2012.
3. Sen B, Peng, Tang X, Erickson H, Galindo H, Mazumdar T, Stewart DJ, Wistuba, Johnson FM. Inactivating BRAF mutations confer dasatinib sensitivity in lung cancer. American Association for Cancer Research Annual Meeting, Chicago, Illinois, 3/2012.
4. Sen B, Peng S, Saigal B, Williams M, Johnson FM. Differential interactions between c-Src and c-Met mediate resistance to c-Src inhibitors. American Association Annual Meeting, Orlando, FL (#1046), 4/2011.
5. Peng S, Saintigny P, Minna J, Zhang L, Lippman SM, Heymach J, Wistuba I, Sen B, Johnson FM. EphA4 is a novel tumor suppressor in lung adenocarcinoma. American Association for Cancer Research Annual Meeting, Orlando, FL (#11945), 4/2011.
6. Sen B, Peng S, Johnson FM. JAK/STAT activation following Src inhibition is mediated by the loss of SOCS2 expression. American Association for Cancer Research (#4005), 2010.
7. Johnson FM, Bekele Nebiyou B, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus J, Hwang L, Takebe N, Blumenschein G, Lippman S, Stewart D. Phase II Study of Dasatinib in Patients with Advanced Non–Small Cell Lung Cancer. American Society of Clinical Oncology (#7594), 2010.
8. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in JAK activation and cancer cell survival via altered SOCS expression. American Association for Cancer Research, Denver CO (#4375), 3/2009. PMID: 19223541.
9. Byers AL, Sen B, Saigal B, Nanjundam, Mills G, Heymach J, Johnson FM. Reciprocal regulation of Src and STAT3 activation in non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Denver CO (#1531), 2009.
10. Brannan JM, Ozburn NC, Prudkin ML, Dong W, Bekele BN, Wistuba II, Johnson FM. Knockdown of the tyrosine kinase EphA2 leads to decreased migration and colony size in non-small cell lung cancer (NSCLC) cell lines. American Association for Cancer Research Annual Meeting (#3535), 2008.
11. Raju U, Johnson FM, Glisson BS, Riesterer O, Milas L, Ang KK. Mechanisms of enhanced radiosensitivity of human head and neck squamous cell carcinomas by dasatinib (BMS-354825, an inhibitor of Src kinases) include induction of apoptosis and inhibitionof DNA repair. American Association for Cancer Research Annual Meeting, San Diego, CA (#642), 2008.
12. Saigal B,Johnson FM. Pathways mediating apoptosis and cell cycle arrest downstream of Src family kinases in aerodigestive tumors. American Association for Cancer Research Annual Meeting (#4864), 2008.
13. Sen B, Saigal B, Johnson F. STAT3 knock down following Src kinase inhibition enhances apoptosis. American Association for Cancer Research Annual Meeting, San Diego, CA (#5274), 2008.
14. Saigal B, Donato N, Tran HT, Johnson FM. Abrogation of STAT3 reactivagtion after Src kinase inhibition results in synergistic anti-tumor effects. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#2382), 2007.
15. Xu L, Nilsson MB, Hanrahan E, Cascone T, Yang Y, Du D, Prudkin L, Liu D, Engelman, J, Johnson F, Kurie J, Wistuba I, Heymach JV. Activated EGFR regulates invasiveness of Non-Cell Lung Cancer through HIF-1α mediated MET expression and is associated with increased Met levels in tumors from NSCLC patients. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#345), 2007.
16. Tsao A, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba II, Johnson FM. Activated Src kinase is expressed in malignant pleural mesothelioma tumors; dasatinib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois (#7713), 2007.
17. Raju U, Koto M, Johnson FM, Glisson B, Milas L, Ang K. Molecular determinants of head and neck squamous cell carcinoma radioresistance. Molecular determinants of head and neck squamous cell carcinoma radioresistance: A novel treatment strategy to improve radiotherapy outcome. American Association for Cancer Research Annual Meeting, Los Angles, CA (#3108), 2007.
18. Luo F , Wu C, McCann B, Mayfield S, Johnson F, Burris S, Chiappori A, Rosen L, Galbraith S, Blackwood-Chirchir A. Phase I Study (CA180021-Segment 1) to evaluate the effect of ketoconazole on the pharmacokinetics of dasatinib in patients with advanced solid tumors. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#932), 2007.
19. Glisson B, Saigal B, Xu Y, Johnson F. Sequence-dependent cytoxicity of docetaxel and erlotinib in head and neck squamous cell carcinoma (HNSCC). American Society of Clinical Oncology Annual Meeting, Chicago, Illinois (#6084), 2007.
20. Kopetz S, Wu J, Donato N, Davies M, Parikh N, Gallick G, Johnson F. Synergistic activity of Src and EGFR inhibitors in colon cancer. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#4079), 2007.
21. Brannan JM, Ozburn NC, Prudkin ML, Massarelli E, Bekele BN, Lopez-Berestein G, Sood AK, Wistuba II., Johnson FM. The presence of Ras mutations in NSCLC tissues correlates with increased expression of the receptor tyrosine kinase EphA2. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#2364), 2007.
22. Bakkannagari S, Saigal B, He D, Wistuba I, Hong WK, Johnson FM, Tsao AS. Inhibition of Src kinase in mesothelioma cell lines leads to cytotoxicity, inhibition of migration, and decreased invasion. American Association for Cancer Research Annual Meeting, Washington, D.C (#3795), 2006.
23. Zhang J, Kalyankrishna S, Johnson F, Kurie JK. Src is constitutively activated in non-small cell lung cancer cells with mutant epidermal growth factor receptor and contributes to cell surviva. American Association for Cancer Research Annual Meeting, Washington, DC (#171), 2006.
24. Johnson FM, Saigal B, Talpaz M, Donato NJ. BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells. American Association for Cancer Research Annual Meeting, Anaheim, CA (#674), 2005.
25. Johnson FM, Tran HT, Johanson MJ, Prieto VG, Tamboli P, Peeples B, Glisson BS. Phase I trial of imatinib mesylate, cisplatin, and irinotecan in small cell lung cancer. International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, IL, 2004.
26. Johnson FM, Garden A, Kies M, Clayman G, Brumfield B, Khuri F, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for patients with low T, High N stage nasophryngeal carcinoma. American Society of Clinical Oncology Annual Meeting, Chicago, IL (#2053), 2003.
27. Johnson FM, Yang P, Newman RA, Talpaz M, Donato NJ. The tyrosine kinase inhibitor ST1571 induces COX-2 expression and PGE2 accumulation in head and neck squamous cell carcinoma (HNSCC) via activation of MAPK. American Association for Cancer Research Annual Meeting, Washington, D.C. (#4862), 2003.
28. Johnson FM, Donato NJ, Talpaz M. Gleevec induces cell cycle arrest, apoptosis, and activation of MAPK in head and neck squamous carcinoma cells. American Association for Cancer Research Annual Meeting, San Francisco, California (#4192), 2002.
29. Johnson FM, Kurie JM, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I trial of weekly etoposide, cisplatin, and irinotecan with G-CSF in patients with small cell lung cancer. American Society of Clinical Oncology Annual Meeting,Orlando, Flordia (#1244), 2002.
30. Johnson FM and Shur BD. Cell Surface ß1,4-galactosyltransferase facilitates invasion and metastasis of K1735 murine melanoma cells. American Association for Cancer Research, Cancer: the interface between basic and applied research, Baltimore, MD (#438), 1995.

Book Chapters

1. Johnson FM and Gallick GE. Src Family Kinase Inhibitors in Cancer Therapy. In: In Serpins and Protein Kinase Inhibitors. Ed(s) Georgiev B, Markovski S. Nova Science Publishers, Inc., 2009.
2. Johnson FM and Pisters KM. Non-small Cell Lung Cancer. In: MD Anderson Manual of Clinical Oncology. Ed(s) Kantarjian HN, Koller CM, Wolff R. McGraw Hill: New York, NY, 2006.
3. Kim ES, Johnson FM, Hong WK, Khuri FR. Strategies in the Chemoprevention of Lung Cancer. In: Cancer Chemoprevention. Ed(s) Koller G, Hawk ET, Sigman CC. Human Press: Totowa, NJ, 2004.

Grant & Contract Support

Title: Predicting and overcoming chemoradioresistance in p53-mutant head and neck cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Jefrey N. Myers
Duration: 7/1/2014 - 6/30/2019
 
Title: Mechanisms that regulate therapeutic response to polo-like kinase inhibitors in non-small cell lung cancer
Funding Source: Lung Cancer Research Foundation
Role: Principal Investigator
Duration: 9/1/2013 - 8/31/2015
 
Title: A Phase I Trial of Dasatinib in Combination with Crizotinib in Patients with Advanced Malignancies
Funding Source: Molecular Evaluation and/or Biopsy Related Support Program (MEBRS)
Role: Co-Principal Investigator
Duration: 8/30/2013 - 8/31/2015
 
Title: Cancer Center Support (CCSG) Grant – Head and Neck Program 5
Funding Source: NIH/NCI
Role: Co-Program Leader
Duration: 7/1/2013 - 6/30/2018
 
Title: BRAF-mediated senescence in lung cancer
Funding Source: American Lung Association
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2014
 
Title: Targeting c-Src in Head and Neck Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2010 - 12/31/2014
 
Title: A Phase 3, Randomized, Open-label study of the efficacy and safety of PF-0234106 versus standard of care chemotherapy.
Funding Source: Pfizer Pharmaceuticals
Role: Principal Investigator
Duration: 11/19/2009 - 11/30/2014
 
Title: A Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Cancer (NSCLC)
Funding Source: Pfizer Pharmaceuticals
Role: Principal Investigator
Duration: 11/19/2009 - 11/18/2014
 
Title: Phase I-II study of Dasatinib and Erlotinib in non-small cell lung cancer
Funding Source: OSI Pharmaceuticals
Role: Principal Investigator
Duration: 1/7/2009 - 1/31/2014
 
Title: The Receptor Tyrosine Kinase EphA2: A Potential Therapeutic Target for EGFR-Dependent Lung Cancers
Funding Source: Joan Scarangello Foundation
Role: Principal Investigator
Duration: 1/1/2009 - 12/31/2010
 
Title: SPORE in Lung Cancer
Funding Source: NIH
Role: Investigator
Principal Investigator: Minna J, Roth J
Duration: 5/1/2008 - 4/30/2011
 
Title: Phase II Study of Dasatinib in Non-small Cell Lung Cancer
Funding Source: Commonwealth Foundation for Cancer Research
Role: Principal Investigator
Duration: 7/1/2007 - 12/31/2009
 
Title: Developmental Research Project
Funding Source: The University of Texas SPORE in Head and Neck Cancer
Role: Principal Investigator
Duration: 3/1/2007 - 4/30/2008
 
Title: Career Development Award
Funding Source: The University of Texas SPORE in Lung Cancer
Role: Principal Investigator
Duration: 9/1/2006 - 4/30/2007
 
Title: Early Therapeutics Development with Phase II Emphasis
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 1/1/2006 - 9/30/2011
 
Title: Physician Scientist Award Grant
Funding Source: MD Anderson Cancer Center
Role: Investigator
Duration: 9/1/2003 - 9/1/2008
 
Title: Head & Neck SPORE
Funding Source: NIH/NCI
Role: Co-Program Leader
Duration: 9/30/2002 - 7/31/2013

Last updated: 1/17/2014